Liu Xinyi, Liu Sitong, Ren Runtao, Wang Xue, Han Chunyu, Liu Zhandong
Department of Neurology, Health Care Centre, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Front Neurosci. 2024 Jan 5;17:1286340. doi: 10.3389/fnins.2023.1286340. eCollection 2023.
Chronic fatigue syndrome (CFS) is a clinical disease that affects multiple body systems. It is characterized by persistent or recurring fatigue, which may be linked to immune, neuroendocrine, and energy metabolism dysfunctions. Individuals with CFS may experience pain, sleep disorders, anxiety, and depression. This research analyzed the fundamental characteristics of anxiety/depression symptoms in patients with CFS and investigated the association between these symptoms and the P50 SG (sensory gate) ratio.
Two hundred and forty-nine subjects fulfilled the CDC-1994 criteria for CFS and were included in the study. The subjects successively completed the Symptom CheckList-90-Revised (SCL-90-R), Hamilton Anxiety Rating Scale-14 (HAMA-14), and Hamilton Depression Rating Scale-24 (HAMD-24). Auditory-evoked potential P50 were measured using the 128-lead-electroencephalograph.
According to HAMA and HAMD, 17.3% ( = 43) of the patients did not exhibit anxiety/depression, with a threshold score of 7 and 7 for HAMA and HAMD. When the threshold score was 14 and 20 respectively, 43.3% ( = 108) of the patients did not exhibit anxiety/depression. The SCL-90-R results indicated that 69.5% ( = 173) of these individuals with the score arranging from 0 to 160 did not present mental problems. There was a correlation between somatization scores and P50 SG ratio in the overall sample and no anxiety or depression (NAOD) group delimited by 14 and 20, respectively, ( < 0.05). Regression analysis showed that anxiety and depression were risk factors associated with an abnormal P50 SG ratio.
A significant correlation exists between the P50 SG ratio and clinical symptoms such as fatigue, anxiety, and depression. Abnormalities in brain function among patients with CFS may play a crucial role in the pathogenesis of the condition, leading to their classification as being prone to functional neurological disorders. The P50 SG ratio cannot be used as a diagnostic marker for CFS but show some significance on the mechanism, classification, treatment, and prognosis of CFS.
慢性疲劳综合征（CFS）是一种影响多个身体系统的临床疾病。其特征为持续性或复发性疲劳，这可能与免疫、神经内分泌及能量代谢功能障碍有关。CFS患者可能会经历疼痛、睡眠障碍、焦虑和抑郁。本研究分析了CFS患者焦虑/抑郁症状的基本特征，并调查了这些症状与P50 SG（感觉门控）比率之间的关联。
249名受试者符合CFS的CDC - 1994标准并纳入本研究。受试者依次完成症状自评量表-90修订版（SCL - 90 - R）、汉密尔顿焦虑量表-14（HAMA - 14）和汉密尔顿抑郁量表-24（HAMD - 24）。使用128导脑电图仪测量听觉诱发电位P50。
根据HAMA和HAMD，17.3%（n = 43）的患者未表现出焦虑/抑郁，HAMA和HAMD的阈值分数分别为7分和7分。当阈值分数分别为14分和20分时，43.3%（n = 108）的患者未表现出焦虑/抑郁。SCL - 90 - R结果表明，这些得分在0至160之间的个体中，69.5%（n = 173）没有精神问题。在总体样本以及分别以14分和20分为界划分的无焦虑或抑郁（NAOD）组中，躯体化得分与P50 SG比率之间存在相关性（P < 0.05）。回归分析表明，焦虑和抑郁是与异常P50 SG比率相关的危险因素。
P50 SG比率与疲劳、焦虑和抑郁等临床症状之间存在显著相关性。CFS患者的脑功能异常可能在该病症的发病机制中起关键作用，导致其被归类为易患功能性神经障碍。P50 SG比率不能用作CFS的诊断标志物，但在CFS的机制、分类、治疗和预后方面具有一定意义。
